866-997-4948(US-Canada Toll Free)

Gastrointestinal Radiation Toxicity - Pipeline Review, H2 2015

Published By :

Global Markets Direct

Published Date : Aug 2015

Category :

Pharmaceutical

No. of Pages : 49 Pages

Gastrointestinal Radiation Toxicity - Pipeline Review, H2 2015

Summary

Global Markets Directs, Gastrointestinal Radiation Toxicity - Pipeline Review, H2 2015, provides an overview of the Gastrointestinal Radiation Toxicitys therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastrointestinal Radiation Toxicity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Radiation Toxicity and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Radiation Toxicity
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gastrointestinal Radiation Toxicity and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gastrointestinal Radiation Toxicity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastrointestinal Radiation Toxicity pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Radiation Toxicity
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Radiation Toxicity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastrointestinal Radiation Toxicity Overview 6
Therapeutics Development 7
Pipeline Products for Gastrointestinal Radiation Toxicity Overview 7
Gastrointestinal Radiation Toxicity Therapeutics under Development by Companies 8
Gastrointestinal Radiation Toxicity Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Gastrointestinal Radiation Toxicity Products under Development by Companies 11
Gastrointestinal Radiation Toxicity Companies Involved in Therapeutics Development 12
Aeolus Pharmaceuticals, Inc. 12
Avaxia Biologics, Inc. 13
RedHill Biopharma Ltd. 14
Soligenix, Inc. 15
Gastrointestinal Radiation Toxicity Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
ABC-294640 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
AEOL-10150 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AVX-470 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
m2A2 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SGX-202 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Gastrointestinal Radiation Toxicity Recent Pipeline Updates 33
Gastrointestinal Radiation Toxicity Dormant Projects 43
Gastrointestinal Radiation Toxicity Product Development Milestones 44
Featured News & Press Releases 44
Aug 01, 2014: Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield in GI ARS 44
Sep 19, 2013: Soligenix Awarded BARDA Contract Valued up to $26.3 Million for Advanced Development of OrbeShield in GI ARS 44
Feb 20, 2013: Soligenix Submits BARDA Contract Proposal For Development Of OrbeShield In Gastrointestinal Acute Radiation Syndrome 45
Jan 29, 2013: Soligenix's OrbeShield Receives FDA Fast Track Designation For Reduction Of Mortality Associated With Gastrointestinal Acute Radiation Syndrome 46
Jan 07, 2013: BARDA Invites Soligenix To Submit Contract Proposal For Development Of OrbeShield In GI ARS 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables
Number of Products under Development for Gastrointestinal Radiation Toxicity, H2 2015 7
Number of Products under Development by Companies, H2 2015 8
Comparative Analysis by Clinical Stage Development, H2 2015 9
Comparative Analysis by Early Stage Development, H2 2015 10
Products under Development by Companies, H2 2015 11
Gastrointestinal Radiation Toxicity Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015 12
Gastrointestinal Radiation Toxicity Pipeline by Avaxia Biologics, Inc., H2 2015 13
Gastrointestinal Radiation Toxicity Pipeline by RedHill Biopharma Ltd., H2 2015 14
Gastrointestinal Radiation Toxicity Pipeline by Soligenix, Inc., H2 2015 15
Assessment by Monotherapy Products, H2 2015 16
Number of Products by Stage and Target, H2 2015 18
Number of Products by Stage and Mechanism of Action, H2 2015 20
Number of Products by Stage and Route of Administration, H2 2015 22
Number of Products by Stage and Molecule Type, H2 2015 24
Gastrointestinal Radiation Toxicity Therapeutics Recent Pipeline Updates, H2 2015 33
Gastrointestinal Radiation Toxicity Dormant Projects, H2 2015 43

List of Figures
Number of Products under Development for Gastrointestinal Radiation Toxicity, H2 2015 7
Number of Products under Development by Companies, H2 2015 8
Comparative Analysis by Early Stage Products, H2 2015 10
Assessment by Monotherapy Products, H2 2015 16
Number of Products by Top 10 Targets, H2 2015 17
Number of Products by Stage and Top 10 Targets, H2 2015 17
Number of Products by Top 10 Mechanism of Actions, H2 2015 19
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 19
Number of Products by Top 10 Routes of Administration, H2 2015 21
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 21
Number of Products by Top 10 Molecule Types, H2 2015 23
Number of Products by Stage and Top 10 Molecule Types, H2 2015 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *